Preparation and evaluation of paclitaxel-loaded nanoparticle incorporated with galactose-carrying polymer for hepatocyte targeted delivery

Drug Development and Industrial Pharmacy

Volumn 38, Issue 9, 2012, Pages 1039-1046

  Wang, Yujie ^a   Jiang, Guoqiang ^a   Qiu, Tingting ^a   Ding, Fuxin ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

ASGP receptor; Drug targeting; HepG2 cells; Nanoparticle; Paclitaxel; Receptor mediated

Indexed keywords

GALACTOSE; PACLITAXEL; POLY(VINYL BENZYLLACTONAMIDE); POLYGLACTIN; POLYMER; POLYVINYL ALCOHOL; ROSE BENGAL; UNCLASSIFIED DRUG;

ADSORPTION; ARTICLE; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; DRUG TRANSPORT; ELECTRIC POTENTIAL; EMULSION; ENDOCYTOSIS; EVAPORATION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; LIVER CELL; NANOENCAPSULATION; PARTICLE SIZE; ZETA POTENTIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL CYCLE; CELL SURVIVAL; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EMULSIFYING AGENTS; ENDOCYTOSIS; GALACTOSE; HEP G2 CELLS; HEPATOCYTES; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; KINETICS; LACTOSE; LIVER NEOPLASMS; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; POLYSTYRENES; POLYVINYL ALCOHOL; SOLUBILITY; SURFACE PROPERTIES;

EID: 84864486101     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2011.637052     Document Type: Article

References (26)

1. Arias JL. (2011). Drug targeting strategies in cancer treatment: An overview. Mini Rev Med Chem, 11:1-17.
2. Liu Y, Miyoshi H, Nakamura M. (2007). Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer, 120:2527-2537.
3. Faraji AH, Wipf P. (2009). Nanoparticles in cellular drug delivery. Bioorg Med Chem, 17:2950-2962.
4. Sinha R, Kim GJ, Nie S, Shin DM. (2006). Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery. Mol Cancer Ther, 5:1909-1917.
5. Chavanpatil MD, Khdair A, Panyam J. (2006). Nanoparticles for cellular drug delivery: Mechanisms and factors influencing delivery. J Nanosci Nanotechnol, 6:2651-2663.
6. Jiang W, Kim BY, Rutka JT, Chan WC. (2008). Nanoparticlemediated cellular response is size-dependent. Nat Nanotechnol, 3:145-150.
7. Decuzzi P, Ferrari M. (2008). The receptor-mediated endocytosis of nonspherical particles. Biophys J, 94:3790-3797.
8. Kasuya T, Kuroda S. (2009). Nanoparticles for human liver-specific drug and gene delivery systems: In vitro and in vivo advances. Expert Opin Drug Deliv, 6:39-52.
9. Fallon RJ, Schwartz AL. (1989). Receptor-mediated delivery of drugs to hepatocytes. Adv Drug Deliv Rev 4:49-63.
10. Wu J, Nantz MH, Zern MA. (2002). Targeting hepatocytes for drug and gene delivery: Emerging novel approaches and applications. Front Biosci, 7:d717-d725.
11. Cho CS, Kobayashi A, Takei R, Ishihara T, Maruyama A, Akaike T. (2001). Receptor-mediated cell modulator delivery to hepatocyte using nanoparticles coated with carbohydrate-carrying polymers. Biomaterials, 22:45-51.
12. Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. (2005). Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release, 105:213-225.
13. Yoo MK, Kim IY, Kim EM, Jeong HJ, Lee CM, Jeong YY et al. (2007). Superparamagnetic iron oxide nanoparticles coated with galactose-carrying polymer for hepatocyte targeting. J Biomed Biotechnol, 2007:94740.
14. Kobayashi K, Sumitomo H. (1985). Synthesis and functions of polystyrene derivatives having pendant oligosaccharides. Polym J, 17:567-575.
15. Feng SS, Mu L, Win KY, Huang G. (2004). Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem, 11:413-424.
16. Singla AK, Garg A, Aggarwal D. (2002). Paclitaxel and its formulations. Int J Pharm, 235:179-192.
17. Wu L, Tang C, Yin C. (2010). Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol). Drug Dev Ind Pharm, 36:439-448.
18. Wang X, Li J, Wang Y, Cho KJ, Kim G, Gjyrezi A et al. (2009). HFT-T, a targeting nanoparticle, enhances specific delivery of paclitaxel to folate receptor-positive tumors. ACS Nano, 3:3165-3174.
19. Hua MY, Yang HW, Chuang CK, Tsai RY, Chen WJ, Chuang KL et al. (2010). Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer. Biomaterials, 31:7355-7363.
20. Xu Z, Gu W, Huang J, Sui H, Zhou Z, Yang Y et al. (2005). In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm, 288:361-368.
21. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. (2002). Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Release, 82:105-114.
22. Ruckenstein E, Manciu M. (2003). Specific ion effects via ion hydration: II. Double layer interaction. Adv Colloid Interface Sci, 105:177-200.
23. Budhian A, Siegel SJ, Winey KI. (2007). Haloperidol-loaded PLGA nanoparticles: Systematic study of particle size and drug content. Int J Pharm, 336:367-375.
24. Dubernet C. (1995). Thermoanalysis of microspheres. Thermochimica, 248:259-269.
25. Hans ML, Lowman AM. (2002). Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mat Sci 6:319-327.
26. Mu L, Feng SS. (2003). PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effects of the emulsifier and drug loading ratio. Pharm Res, 20:1864-1872.